Register

DEADLINE ALERT for MARA, HOOD, RETA, DM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, January 10, 2022
People's Law Office, Telephone, Alport syndrome, Alport, Law, IPO, Suite, Registration statement, Safety, Robin Hood, GLOBE, Class, Time, Chronic kidney disease, Company, Risk, Register, FDA, Trial of the century, Investment, Security (finance), Pharmaceutical industry, Public relations

BENSALEM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

ZME Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Zhangmen Education Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 18, 2022

Retrieved on: 
Monday, January 10, 2022
Legal, Professional Services, Education, Securities Exchange Act of 1934, Registration statement, NYSE, ZME, Court, Review, Company, Register, LLC, PRC

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.
  • or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Zhangmen you have until January 18, 2022, to request that the Court appoint you as lead plaintiff.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Decarbonization Plus Acquisition Corporation II Expects Stockholders to Approve Business Combination with Tritium

Retrieved on: 
Monday, January 10, 2022
Adjournment, Forward-looking statement, Technology, Name, PIPE, Business architecture, Sports Properties Acquisition Corporation, Tritium, SEC, THE, Registration statement, Probability, Risk, NASDAQ, Growth, Proxy, Securities Act of 1933, Form F-4, Riverstone Holdings, AND, Industry, Main Street, Agriculture, Form, Riverstone, Sale, Register, Annual report, Software, Prospectus, Failure, Transport, Investment, Acquisition, Security (finance), NewCo

Decarbonization Plus Acquisition Corporation II is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a target whose principal effort is developing and advancing a platform that decarbonizes the most carbon-intensive sectors.

Key Points: 
  • Decarbonization Plus Acquisition Corporation II is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a target whose principal effort is developing and advancing a platform that decarbonizes the most carbon-intensive sectors.
  • Certain statements made in this document are "forward-looking statements" with respect to the proposed business combination, including statements regarding the results of the special meeting of stockholders of DCRN.
  • Additional information regarding the interests of such participants is set forth in the Registration Statement for the proposed business combination.
  • A list of the names of such directors and executive officers and information regarding their interests in the business combination is contained in the Registration Statement for the proposed business combination.

JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Securities Act of 1933, Chemical patent, Immortalised cell line, Degenerative disease, Business architecture, Person, Annual report, Program, Registration statement, Partnership, Communication, FDA, Laboratoires Pierre Fabre, Acquisition, Oaktree Capital Management, Goal, Sale, U.S. Securities and Exchange Commission, CEO, Solution, Prospectus, SEC, Form, Injection, Terminology, Failure, Patient, Multimedia, Vitamin, NYSE, S.A.S, Compliance, Chinese patent medicine, BLA, Risk, Health Canada, Growth, Name, Cancer, NASDAQ, Forward-looking statement, Register, USD, Review, Business, Osteoporosis, Inflammation, Generic drug, Pharmaceutical industry, Fine chemical, Security (finance), IQVIA, EU, Adalimumab, JAMP Pharma Group, Alvotech, AVT02, JAMP PHARMA GROUP, ALVOTECH, AVT02

JAMP has accordingly been issued notices of compliance for these presentations of SIMLANDI and can launch them in Canada.

Key Points: 
  • JAMP has accordingly been issued notices of compliance for these presentations of SIMLANDI and can launch them in Canada.
  • Mark Levick, CEO of Alvotech, added, We are delighted by the approval from Health Canada, which highlights Alvotechs global approach to biosimilars, and look forward to continued collaboration with JAMP.
  • SIMLANDI is a high-concentration, citrate-free biosimilar to Humira, which is used to treat a range of certain inflammatory conditions.
  • In January 2020, JAMP Pharma Group signed an exclusive agreement with Alvotech to collaborate on a broad portfolio of biosimilars.

Gett to Appoint Enterprise Software Veteran Ruth Sun to Board of Directors to scale industry-leading GTM platform

Retrieved on: 
Monday, January 10, 2022
Software, Technology, Other Technology, IBM, Force, Form F-4, Person, EVP, Government, Registration statement, Communication, XV, Glass, ESG, Acquisition, U.S. Securities and Exchange Commission, Transport, CEO, VP, Technology, Prospectus, 100,000, SEC, B2B, Form, Pub chain, GTM, Pains, Failure, Software as a service, Blackboard, Arctic Sun medical device, Probability, Therapy, SEC filing, Â, COVID-19, Intellectual property, Hackensack Meridian Health, Form S-1, Risk, Reading, IBM Watson Health, NASDAQ, Forward-looking statement, Register, Sun, Xi, Management, Renewable energy, Taxicab, Security (finance), Risk management, Tempest, Ownership, Cabify, Gett, Nasdaq, Growth

At every step of her career, Ruth has been responsible for transformational growth while maintaining commitment to diversity and inclusion.

Key Points: 
  • At every step of her career, Ruth has been responsible for transformational growth while maintaining commitment to diversity and inclusion.
  • Additionally, Sun was the President and Co-founder of Sun Medical, which was acquired by Hackensack Meridian Health in 2020.
  • Gett is a technology platform focused on solving corporate Ground Transportation Management (GTM) challenges, where spending is estimated to exceed $100 billion globally.
  • Upon closing of the business combination, the newly combined company will operate as Gett and trade on the Nasdaq under the symbol GETT.

Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Memorial Sloan Kettering Cancer Center, SEC, Safety, Form, Risk, Skin, Acquisition, Alpha Sigma Tau, Shareholder, Neoplasm, Failure, Business architecture, Security (finance), 100,000, Name, Memorial, Patient, Commissioner, Sale, U.S. Securities and Exchange Commission, HCCC, Securities Act of 1933, Register, Mergers and acquisitions, Registration statement, Alpha Tau Delta, Research, RECIST, Skin cancer, Tripura Merger Agreement, Private Securities Litigation Reform Act, Sumathi Best Television Current Reporting Award, Nasdaq, Technology, XV, Prospectus, News, COVID-19, FDA, Xi, Business, Radiation, Vii, Medical imaging, Pharmaceutical industry, Alpha, Tel Aviv University

Alpha Tau CEO Uzi Sofer remarked, "Alpha Tau is incredibly focused on the US market, which we see as the paramount market for the Alpha DaRT.

Key Points: 
  • Alpha Tau CEO Uzi Sofer remarked, "Alpha Tau is incredibly focused on the US market, which we see as the paramount market for the Alpha DaRT.
  • "We are extremely encouraged by the initial efficacy results from our US pilot trial," said Alpha Tau CMO, Dr. Robert Den.
  • We look forward to continued examination of the potential of the Alpha DaRT, backed by the expediency of the FDA's breakthrough device designation."
  • Achieving a 100 percent complete response rate for a new cancer therapy with no product-related serious adverse events is remarkable."

NuScale Power Announces Filing of a Registration Statement on Form S-4 in Connection With Its Proposed Business Combination With Spring Valley Acquisition Corp.

Retrieved on: 
Monday, January 10, 2022
Other Energy, Professional Services, Utilities, Nuclear, Alternative Energy, Energy, Technology, Environment, Engineering, Finance, Other Technology, Manufacturing, Securities Act of 1933, LinkedIn, SEC, Form, SMR, NuScale Power, Acquisition, Electricity, Watt, Business architecture, Securities Exchange Act of 1934, SV, Water, Sale, NASDAQ, Person, CRIMINAL, Forward-looking statement, U.S. Securities and Exchange Commission, Instagram, Facebook, Register, Registration statement, Multimedia, Private Securities Litigation Reform Act, Risk, NPM, Nasdaq, Technology, Prospectus, Twitter, LLC, Recycling, THE, Security (finance), NuScale Power, Spring Valley Acquisition Corp., NUSCALE POWER, SPRING VALLEY ACQUISITION CORP.

The Registration Statement contains information about the proposed Business Combination, including an overview of NuScales business, terms of the transaction, pro-forma financial information and risk factors.

Key Points: 
  • The Registration Statement contains information about the proposed Business Combination, including an overview of NuScales business, terms of the transaction, pro-forma financial information and risk factors.
  • While Spring Valley and NuScale may elect to update these forward-looking statements at some point in the future, Spring Valley and NuScale specifically disclaim any obligation to do so.
  • The proposed Business Combination will be submitted to shareholders of Spring Valley for their approval.
  • The Registration Statement that Spring Valley has filed with the SEC includes a proxy statement/prospectus, which will be distributed to Spring Valleys shareholders in connection with Spring Valleys solicitation of proxies for the vote on the proposed Business Combination.

NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms

Retrieved on: 
Monday, January 10, 2022
Pharmaceutical, Health, Optical, People, Health, Hypochlorous acid, Pain, Form, No, Tears, Security (finance), Patient, U.S. Securities and Exchange Commission, Eye, Blepharitis, Register, Sore, Multimedia, Smoke, NYSE, American Optometric Association, OTC, Private Securities Litigation Reform Act, Amazon (company), NovaBay Pharmaceuticals, Wind, Meibomian gland, LLC, Inflammation, Lens (anatomy), Pharmaceutical industry, Online shopping, Cosmetics

These lubricating eye drops feature innovative ingredients and a mode of action thats new to the eyecare market and formulated to bring immediate relief to those who suffer from the symptoms of dry eye.

Key Points: 
  • These lubricating eye drops feature innovative ingredients and a mode of action thats new to the eyecare market and formulated to bring immediate relief to those who suffer from the symptoms of dry eye.
  • (Photo: Business Wire)
    The Lubricating Eye Drops are an especially good value when compared to competitors, with two 15ml bottles sold as a twin pack for $19.99.
  • Lubricating eye drops are the first-line, go-to product for treating the symptoms of dry eye because they can provide immediate relief from the discomfort and pain thats often associated with this common condition, said Justin Hall, NovaBay CEO.
  • 1 eyelid and lash cleanser in the U.S. dry eye market and is the only product clinically proven to treat the underlying cause of bacterial dry eye.

LION ELECTRIC REACHES KEY MILESTONE WITH POSSESSION OF JOLIET, ILLINOIS PRODUCTION FACILITY AND KEY MANAGEMENT APPOINTMENTS

Retrieved on: 
Monday, January 10, 2022
SEC, Form, Lists of disasters, Growth, Accuride Corporation, Environment, Vaccination, Alstom, TSX, Risk, Bombardier Transportation, Security (finance), Lion Electric Company, Nature, Person, U.S. Securities and Exchange Commission, New, Quality control, Transport, Forward-looking statement, Register, Toronto Stock Exchange, LEV, Registration statement, Multimedia, Review, Senior, NYSE, Company, AMF, Pratt & Whitney, Prospectus, COVID-19, Perception, SEC filing, Strategic Initiative for Women in the Horn of Africa, Renewable energy, Management, Hunting, Risk management, Operation

The facility is expected to add up to 1,400 clean energy jobs in the region over the next four years.

Key Points: 
  • The facility is expected to add up to 1,400 clean energy jobs in the region over the next four years.
  • Lion also announced the hiring of two new positions key to the company's growth.
  • He will coordinate with all departments to ensure that Lion's strategic governance plan is consistent with the company's growth.
  • Always actively seekingnew and reliable technologies, Lion vehicles have unique featuresthat are specifically adapted to its users and their everydayneeds.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Organogenesis, Paysafe, Revance Therapeutics, and Cloopen Group and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 10, 2022
Paysafe, Shareholder, Medicare, Organogenesis, Gambling, Federation, NASDAQ, Defendant, Register, Registration statement, Therapy, Solution, Digital wallet, NYSE, Company, E-commerce, Lists of schools in England, Human, FDA, GLOBE, RAAS, Audit, Risk management, P.C

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • In fact, as the Cloopen class action lawsuit alleges, Cloopens growth strategy was not working and its existing customers were abandoning the company.
  • For more information on the Cloopen Group class action go to: https://bespc.com/cases/RAAS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.